Schedule 13G ownership disclosure
Akebia Therapeutics Inc
Common Stock · CUSIP: 00972D105
Event date: 2025-03-31
- Filing-level shares
- 12,685,803
- Percent of class
- 5.37%
- The Vanguard Group
Shares: 12,685,803 · Class: 5.37%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-25-000479
- Form type
- SCHEDULE 13G
- Filer
- Akebia Therapeutics, Inc.
- CIK
- CIK 1517022
- Filed
- Apr 30, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership